{"id":"iv-control","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is typically achieved through the use of a pump or other device that regulates the flow of medication. The goal is to ensure a consistent and controlled delivery of the medication to the patient.","oneSentence":"IV Control is used to control the rate of intravenous medication administration.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:58.022Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control of intravenous medication administration"}]},"trialDetails":[{"nctId":"NCT05657873","phase":"PHASE2","title":"A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-12-09","conditions":"Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma","enrollment":68},{"nctId":"NCT07497009","phase":"NA","title":"Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial.","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-12-23","conditions":"Neurocognitive Function of Elderly Patients Post Operation","enrollment":30},{"nctId":"NCT02306161","phase":"PHASE3","title":"Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-12","conditions":"Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow","enrollment":312},{"nctId":"NCT07435077","phase":"PHASE4","title":"Examining Analgesic Synergy and Efficacy in Trauma Care","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":282},{"nctId":"NCT07497451","phase":"NA","title":"Enhancing Pain Management Among Patients Diagnosed With Stage III and Stage IV of Breast Cancer: The Power of Immersive and Non-Immersive Virtual Reality-Driven Interactive Guided Imagery","status":"NOT_YET_RECRUITING","sponsor":"Middle East University","startDate":"2026-03-20","conditions":"Cancer Pain, Virtual Reality Immersion","enrollment":90},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290},{"nctId":"NCT03648905","phase":"","title":"Clinical Laboratory Evaluation of Chronic Autonomic Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2018-09-06","conditions":"Parkinson's Disease, Multiple System Atrophy, Autonomic Failure","enrollment":89},{"nctId":"NCT06459180","phase":"PHASE3","title":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-24","conditions":"Cervical Cancer","enrollment":686},{"nctId":"NCT07498309","phase":"PHASE3","title":"Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-09","conditions":"Vaso-Occlusive Crises, Sickle Cell Disease","enrollment":144},{"nctId":"NCT05691478","phase":"PHASE2, PHASE3","title":"A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-03","conditions":"High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma","enrollment":1122},{"nctId":"NCT04199104","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-05","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":511},{"nctId":"NCT07309393","phase":"NA","title":"Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-12-31","conditions":"Residual Neuromuscular Block","enrollment":240},{"nctId":"NCT07496372","phase":"PHASE3","title":"Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart Failure (NYHA Class III-IV)","status":"NOT_YET_RECRUITING","sponsor":"Help Therapeutics","startDate":"2026-04-30","conditions":"Heart Failure","enrollment":80},{"nctId":"NCT03969004","phase":"PHASE3","title":"Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2019-06-04","conditions":"Cutaneous Squamous Cell Carcinoma","enrollment":415},{"nctId":"NCT06128629","phase":"PHASE3","title":"MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)","status":"RECRUITING","sponsor":"Intellia Therapeutics","startDate":"2023-12-13","conditions":"Transthyretin Amyloidosis (ATTR) With Cardiomyopathy","enrollment":1200},{"nctId":"NCT06858579","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)","status":"RECRUITING","sponsor":"Dianthus Therapeutics","startDate":"2025-02-10","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":480},{"nctId":"NCT07494383","phase":"NA","title":"Sphenopalatine Ganglion Block for Post-Dural Puncture Headache: A Pilot Randomised Controlled Trial","status":"COMPLETED","sponsor":"ISSSTE Hospital Regional \"Gral. Ignacio Zaragoza\"","startDate":"2024-05-21","conditions":"Post-Dural Puncture Headache, Headache","enrollment":26},{"nctId":"NCT06439082","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-24","conditions":"Sickle Cell Disease","enrollment":315},{"nctId":"NCT04785820","phase":"PHASE2","title":"A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-06-25","conditions":"Advanced or Metastatic Esophageal Squamous Cell Carcinoma","enrollment":190},{"nctId":"NCT06954987","phase":"PHASE2","title":"Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-17","conditions":"Acute Myeloid Leukemia","enrollment":244},{"nctId":"NCT07459166","phase":"PHASE2","title":"A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade","status":"NOT_YET_RECRUITING","sponsor":"Clear Scientific, Inc.","startDate":"2026-04","conditions":"Fentanyl Overdose, Fentanyl Poisoning","enrollment":16},{"nctId":"NCT06009926","phase":"PHASE2","title":"Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-04","conditions":"Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Occupational Malignant Neoplasm","enrollment":72},{"nctId":"NCT07210515","phase":"PHASE3","title":"Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)","status":"RECRUITING","sponsor":"Ambros Therapeutics, Inc.","startDate":"2026-03","conditions":"Complex Regional Pain Syndrome Type I","enrollment":270},{"nctId":"NCT04628026","phase":"PHASE3","title":"Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2022-09-13","conditions":"Acute Myeloid Leukemia","enrollment":650},{"nctId":"NCT06602141","phase":"NA","title":"Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise","status":"RECRUITING","sponsor":"AdventHealth Translational Research Institute","startDate":"2024-09-11","conditions":"Obesity","enrollment":70},{"nctId":"NCT01386385","phase":"PHASE1, PHASE2","title":"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":"Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma","enrollment":53},{"nctId":"NCT03914612","phase":"PHASE3","title":"Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma","enrollment":813},{"nctId":"NCT06132256","phase":"PHASE2","title":"MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2023-12-11","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":145},{"nctId":"NCT04251533","phase":"PHASE3","title":"Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-08","conditions":"Triple Negative Breast Neoplasms","enrollment":137},{"nctId":"NCT07495046","phase":"NA","title":"Low Excision and High Suspension Hemorrhoidectomy Versus Conventional Milligan-Morgan Hemorrhoidectomy for Grade III-IV Mixed Hemorrhoids","status":"NOT_YET_RECRUITING","sponsor":"The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine","startDate":"2026-04-01","conditions":"Mixed Hemorrhoids","enrollment":120},{"nctId":"NCT02122185","phase":"PHASE2","title":"Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2015-02-25","conditions":"Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion","enrollment":111},{"nctId":"NCT06657768","phase":"PHASE1","title":"A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-29","conditions":"Alzheimer Disease, Healthy","enrollment":128},{"nctId":"NCT05724108","phase":"PHASE2","title":"Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-30","conditions":"Metastatic Neuroendocrine Tumor","enrollment":94},{"nctId":"NCT05039840","phase":"PHASE2","title":"Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2021-11-10","conditions":"Systemic Lupus Erythematosus","enrollment":109},{"nctId":"NCT02101775","phase":"PHASE2","title":"Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-07-21","conditions":"Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma","enrollment":124},{"nctId":"NCT05986292","phase":"PHASE2","title":"A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-01-30","conditions":"Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain","enrollment":10000},{"nctId":"NCT06290128","phase":"PHASE3","title":"A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-07-12","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic","enrollment":140},{"nctId":"NCT07498751","phase":"PHASE1","title":"Phase I PK and Safety Study of Ondansetron Inhalation Powder","status":"COMPLETED","sponsor":"Luxena Pharmaceuticals, Inc.","startDate":"2025-03-13","conditions":"Postoperative Nausea and Vomiting","enrollment":24},{"nctId":"NCT07489742","phase":"NA","title":"Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Tonsillectomy","status":"RECRUITING","sponsor":"Tanta University","startDate":"2026-03-25","conditions":"Ondansetron, Lozenge, Intravenous","enrollment":210},{"nctId":"NCT07262060","phase":"PHASE2","title":"Improving Preterm Kidney Outcomes With Caffeine","status":"NOT_YET_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-04","conditions":"Kidney Injury, Pre-Term","enrollment":102},{"nctId":"NCT05139316","phase":"PHASE3","title":"A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)","status":"COMPLETED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2021-11-08","conditions":"Glycogen Storage Disease Type IA","enrollment":49},{"nctId":"NCT07493018","phase":"NA","title":"Effect of Hand Puppet and Squeeze Toys on IV Placement in Pediatric Oncology Patients","status":"NOT_YET_RECRUITING","sponsor":"Akdeniz University","startDate":"2026-05","conditions":"Pediatric Hematology, Pediatric Oncology","enrollment":90},{"nctId":"NCT06247345","phase":"PHASE1","title":"A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01","status":"SUSPENDED","sponsor":"Alzheimer's Disease Expert Lab (ADEL), Inc.","startDate":"2024-02-06","conditions":"Alzheimer Disease","enrollment":73},{"nctId":"NCT07407140","phase":"PHASE3","title":"VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-30","conditions":"AML, Adult","enrollment":300},{"nctId":"NCT06252649","phase":"PHASE3","title":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-07-17","conditions":"Metastatic Colorectal Cancer","enrollment":450},{"nctId":"NCT06745908","phase":"PHASE3","title":"ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-10-01","conditions":"NSCLC Stage IV","enrollment":460},{"nctId":"NCT05806060","phase":"PHASE3","title":"Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-04-25","conditions":"Triple-Negative Breast Cancer","enrollment":134},{"nctId":"NCT06834035","phase":"PHASE1, PHASE2","title":"Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa","status":"RECRUITING","sponsor":"M. Peter Marinkovich","startDate":"2025-08-04","conditions":"Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita, Dystrophic Epidermolysis Bullosa","enrollment":8},{"nctId":"NCT06830798","phase":"PHASE3","title":"Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-02-24","conditions":"Delayed Graft Function, DGF, Kidney Transplant","enrollment":450},{"nctId":"NCT07211958","phase":"PHASE3","title":"Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation","status":"RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2025-11-25","conditions":"Acute Myeloid Leukemias","enrollment":468},{"nctId":"NCT06850103","phase":"PHASE2","title":"SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-04-22","conditions":"Colorectal Carcinoma, Oligometastases, pMMR","enrollment":51},{"nctId":"NCT06903819","phase":"PHASE4","title":"Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients","status":"RECRUITING","sponsor":"Texas Tech University Health Sciences Center","startDate":"2025-11-06","conditions":"Orthopedic Trauma Surgery Patients, Postoperative Pain, Opioid Use","enrollment":90},{"nctId":"NCT07033039","phase":"NA","title":"Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre","status":"RECRUITING","sponsor":"University of Nove de Julho","startDate":"2026-01-30","conditions":"Rhinoplasty, Edema","enrollment":60},{"nctId":"NCT07423650","phase":"PHASE4","title":"Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy","status":"RECRUITING","sponsor":"Iuliu Hatieganu University of Medicine and Pharmacy","startDate":"2026-03","conditions":"Pancreatoduodenectomy, Pain Management, Opioid Analgesia","enrollment":93},{"nctId":"NCT07221474","phase":"PHASE2","title":"A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-12","conditions":"Squamous Non-small Cell Lung Cancer","enrollment":180},{"nctId":"NCT07241988","phase":"NA","title":"Virtual Reality and White Noise During Peripheral IV Catheterization in Adults","status":"COMPLETED","sponsor":"Gizem Göktuna","startDate":"2025-10-11","conditions":"Peripheral Intravenous Catheterization, Pain, Anxiety","enrollment":76},{"nctId":"NCT06077760","phase":"PHASE3","title":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-06","conditions":"Non-small Cell Lung Cancer","enrollment":868},{"nctId":"NCT06937099","phase":"PHASE3","title":"Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-06-26","conditions":"Crohn's Disease, Obesity or Overweight","enrollment":290},{"nctId":"NCT07490457","phase":"NA","title":"Intraoperative Ketamine for Chronic Postoperative Pain After Open-Heart Surgery","status":"NOT_YET_RECRUITING","sponsor":"Bursa City Hospital","startDate":"2026-04-15","conditions":"Cardiac Anaesthesia, Chronic Pain, Post Operative Pain, Chronic","enrollment":100},{"nctId":"NCT07476859","phase":"PHASE4","title":"Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome","status":"RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2026-03-05","conditions":"Acute Coronary Syndromes (ACS), Iron Deficiencies, Elderly (People Aged 65 or More)","enrollment":538},{"nctId":"NCT05065216","phase":"PHASE2, PHASE3","title":"Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)","status":"RECRUITING","sponsor":"DiaMedica Therapeutics Inc","startDate":"2021-11-07","conditions":"Acute Stroke, Ischemic Stroke, Stroke","enrollment":728},{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT06937086","phase":"PHASE3","title":"Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-06-26","conditions":"Ulcerative Colitis, Obesity or Overweight","enrollment":350},{"nctId":"NCT06890598","phase":"PHASE3","title":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-03-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":700},{"nctId":"NCT02941289","phase":"NA","title":"Visuospatial Attention, Eye Movements and Instrumental Activities of Daily Living (IADLs) in Alzheimer's Disease","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2017-04-27","conditions":"Alzheimer's Disease","enrollment":48},{"nctId":"NCT07276958","phase":"PHASE1","title":"A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-04","conditions":"Healthy, Systemic Lupus Erythematosus, Rheumatoid Arthritis","enrollment":63},{"nctId":"NCT07488533","phase":"PHASE2","title":"Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-01","conditions":"Non-Clear Cell Renal Cell Carcinoma","enrollment":40},{"nctId":"NCT06915025","phase":"PHASE3","title":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer","status":"RECRUITING","sponsor":"Imunon","startDate":"2025-07-09","conditions":"Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer","enrollment":500},{"nctId":"NCT07486934","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of DYNE-101 in Participants With Myotonic Dystrophy Type 1","status":"NOT_YET_RECRUITING","sponsor":"Dyne Therapeutics","startDate":"2026-04","conditions":"Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy","enrollment":150},{"nctId":"NCT06938776","phase":"NA","title":"Interactive Musical Toy Reduces Pain and Fear During IV Cannulation in Preschool Children","status":"COMPLETED","sponsor":"Trakya University","startDate":"2025-05-15","conditions":"Pain Management","enrollment":64},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT05911295","phase":"PHASE3","title":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2023-09-22","conditions":"Urothelial Carcinoma","enrollment":412},{"nctId":"NCT07485023","phase":"NA","title":"Oral Versus Intravenous Iron for Anemia Diagnosed After 34 Weeks of Gestation","status":"NOT_YET_RECRUITING","sponsor":"University of Roma La Sapienza","startDate":"2026-07-01","conditions":"Anemia Complicating Pregnancy","enrollment":128},{"nctId":"NCT07024823","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-09","conditions":"Chronic Kidney Disease","enrollment":124},{"nctId":"NCT06430801","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-05","conditions":"Crohn's Disease","enrollment":1200},{"nctId":"NCT07169851","phase":"PHASE2","title":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-28","conditions":"Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions","enrollment":204},{"nctId":"NCT05488340","phase":"PHASE2","title":"A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)","status":"RECRUITING","sponsor":"Locus Biosciences","startDate":"2022-07-13","conditions":"Urinary Tract Infections","enrollment":318},{"nctId":"NCT05268289","phase":"PHASE2","title":"Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-08-10","conditions":"Lupus Nephritis","enrollment":240},{"nctId":"NCT07485816","phase":"","title":"A Study on the Correlation Between Cardiac-Cerebral Oxygenation Reserve and Cognitive Function Changes in Heart Failure Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Yan'an Affiliated Hospital of Kunming Medical University","startDate":"2026-03-15","conditions":"Heart Failure (HF)","enrollment":60},{"nctId":"NCT06994897","phase":"PHASE1","title":"A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-13","conditions":"Healthy","enrollment":92},{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":200},{"nctId":"NCT07485101","phase":"NA","title":"Glycemic Targets During CPB in Elderly Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2026-04-01","conditions":"Glycemic Management During CPB in Elderly Diabetic Cardiac Surgery","enrollment":3000},{"nctId":"NCT07483073","phase":"PHASE2","title":"A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-04","conditions":"Colitis, Ulcerative, Crohn Disease","enrollment":60},{"nctId":"NCT06589986","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-09-17","conditions":"Moderately to Severely Active Ulcerative Colitis","enrollment":400},{"nctId":"NCT05923190","phase":"PHASE2","title":"Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2023-06-14","conditions":"Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma","enrollment":60},{"nctId":"NCT07235163","phase":"PHASE1","title":"A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 Are Tolerated and Act in the Body of Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-04-13","conditions":"Healthy","enrollment":100},{"nctId":"NCT07479043","phase":"PHASE3","title":"To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS).","status":"NOT_YET_RECRUITING","sponsor":"Breathe Biologics, Inc.","startDate":"2026-07","conditions":"Acute Respiratory Distress Syndrome","enrollment":128},{"nctId":"NCT07481539","phase":"PHASE2","title":"Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment","status":"RECRUITING","sponsor":"Azienda Sanitaria Universitaria Friuli Centrale","startDate":"2026-03-24","conditions":"Bacteria Infection, Piperacillin, Tazobactam Drug Combination","enrollment":240},{"nctId":"NCT06291376","phase":"PHASE3","title":"Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-03-29","conditions":"Immunoglobulin A Nephropathy, IgAN","enrollment":510},{"nctId":"NCT07218380","phase":"PHASE3","title":"A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-12","conditions":"Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis","enrollment":450},{"nctId":"NCT06995820","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-06","conditions":"Healthy","enrollment":136},{"nctId":"NCT07481929","phase":"","title":"Predictors of Fracture-Dislocation in Schatzker IV Tibial Plateau Fractures: A Reproducible, Quantitative MRI-Based Injury-Pattern Analysis","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2019-01-01","conditions":"Tibial Plateau Fracture","enrollment":77},{"nctId":"NCT05698823","phase":"NA","title":"Regular Home-use of Dual-light Photodynamic Therapy in the Management of Chronic Stage III-IV Periodontitis","status":"COMPLETED","sponsor":"Koite Health Oy","startDate":"2023-06-06","conditions":"Periodontitis Chronic Generalized Moderate, Periodontitis Chronic Generalized Severe","enrollment":56},{"nctId":"NCT06112548","phase":"NA","title":"The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral TKA","status":"COMPLETED","sponsor":"Damascus University","startDate":"2024-03-01","conditions":"Arthritis Knee, Pain, Arthroplasty Complications","enrollment":80},{"nctId":"NCT07175441","phase":"PHASE2","title":"Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Riboscience, LLC.","startDate":"2026-04","conditions":"Advanced Unresectable Hepatocellular Carcinoma","enrollment":220},{"nctId":"NCT03875235","phase":"PHASE3","title":"Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-04-16","conditions":"Biliary Tract Neoplasms","enrollment":810},{"nctId":"NCT04720716","phase":"PHASE3","title":"A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-02-07","conditions":"Hepatocellular Carcinoma","enrollment":344},{"nctId":"NCT06611111","phase":"EARLY_PHASE1","title":"Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease","status":"RECRUITING","sponsor":"State University of New York - Upstate Medical University","startDate":"2025-02-03","conditions":"Post-Treatment Lyme Disease","enrollment":44},{"nctId":"NCT07483099","phase":"PHASE2","title":"A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-04","conditions":"Crohn Disease","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":289,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Saline","Placebo"],"phase":"phase_3","status":"active","brandName":"IV Control","genericName":"IV Control","companyName":"Mallinckrodt","companyId":"mallinckrodt","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IV Control is used to control the rate of intravenous medication administration. Used for Control of intravenous medication administration.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}